🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Kudos Alex Wyatt what a great reflection on cross-disciplinary (scientist-clinician, clinician-scientist) learning and respect inspiring cancer research #ANZUP23

Nice collaboration with Francesca Khani, MD Will Hooper Olivier Elemento Nicolas Robine and many others - Evolution of structural rearrangements in prostate cancer intracranial metastases npj Journals Dana-Farber NY Genome Center Weill Cornell Medicine nature.com/articles/s4169…

#Tweetorial: Data from Drake Lab and others shows CSPC is immunologically different and not an ‘immune desert’ like CRPC. We interrogated CSPC metastases with single-cell RNA-seq (scRNA-seq), VIPER, and IF before and after tx w/ ADT +/- aPD-1 in a Phase 2 study. /1

Does the evolutionary history of a cancer predict outcome? In our pre-print, we introduce a new method to measure a cancer’s past using bulk methylation data. In chronic lymphocytic leukaemia (CLL), these inferred histories are highly prognostic! (1/9) doi.org/10.1101/2023.1…

Our latest study with Piet Ost, of whole prostates, lymph nodes, and ctDNA at initial diagnosis in de novo metastatic prostate cancer (distant mets) is out in Nature Cancer: rdcu.be/du8Tu. 1/n thread 👇

ANZUP celebrates Margaret McJannett as she "retires" (yeah right I suspect there won't be much putting up of feet), and welcomes our new CEO Samantha Oakes

Capping off a month on staff Memorial Sloan Kettering Cancer Center GU Onc. Much exciting work to be done and a fantastic, welcoming team all around Jonathan Rosenberg MD @morr316 Dr. Darren Feldman et al. Thankful to mentors + collaborators along the way Christopher Sweeney, MBBS Dana-Farber Lank Center for Genitourinary Oncology Ian Davis (Bluesky @profiand) ANZUP

TP53: - Discovered 45 years ago, most cited gene all time - No therapies - 500 million people currently living will die of TP53 mutant cancers without new therapies Our Preprint: - A general strategy for TP53 missense mutant cancers (majority) with prototype small molecules

Official now 🤓 Beatriz

Attention all postdocs - this is an incredible opportunity with a wonderful mentor to help advance great science and your career!!!! Uromigos Eli Van Allen Anis Hamid

Great to finally meet all in person! Here we are: ESMO - Eur. Oncology Translational Research Faculty, chaired by Turajlic Lab @ The Crick. #ESMO24 🔬🧪🧑‍🔬 Watch the space for exciting projects ahead! 💡If you have any burning ideas/suggestions re: #TranslationalResearch - feel free to reach out too!

📢 Just published in JCO! What is the optimal chemotherapy for oligodendroglioma patients? Our study using data from the national prospective cohort POLA found better PFS and OS outcomes with first-line RT/PCV compared to RT/TMZ ascopubs.org/doi/10.1200/JC…

Great pod ⁦GU Cast | Urology podcast!⁩ ! thanks for sharing ⁦Christopher Sweeney, MBBS⁩ ⁦Ian Davis (Bluesky @profiand)⁩ thanks for doing ⁦ANZUP⁩ looking fwd to further correlatives analyses ⁦Anis Hamid Lisa Horvath podcasts.apple.com/us/podcast/gu-…

The mechanism underlying the progression of castration-resistant prostate cancer! This month’s cover features work by Katherine Morel Beatriz Christopher Sweeney, MBBS ExpressionEngine & team showing Tristetraprolin regulates phenotypic plasticity of prostate cancer: jci.org/articles/view/…

Latest journey in #prostatecancer cell plasticity. Team effort Christopher Sweeney, MBBS Katherine Morel Beatriz Work stems from previous Christopher Sweeney, MBBS investigations in NFkB regulation by tristetraprolin (TTP; gene ZFP36), and generation of the NFkBi dimethylaminoparthenolide (DMAPT)

The MSK GU Service recently celebrated the illustrious career of Dr. Dean Bajorin. We will miss his wisdom, insight, humor, mentorship, and leadership, but look forward to his continued input as an Emeritus Member at MSK (w/guest star Dr. Bosl).

Incredible prognostic power of PSMA PET from the updated PROMISE large international registry (PPP2): 3 and 5-yr survival data. Superior to NCCN risk score. Data across initial stage, biochemical recurrence, "non-metastatic" castration-resistant, mSPC, MCRPC !! Just out in

On the eve of #ASCO25, I am delighted to share results from the correlative analyses of the ANZUP phase II TheraP study, now published in Nature Medicine. Massive effort supported by dedicated co-investigators, coordinators, patients & families from 11 study sites across

Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer Nature Communications rdcu.be/euijO Team science led by Kei Mizuno #BeltranLab Dana-Farber Lank Center for Genitourinary Oncology PCF Science

1/ Recently, our lab has worked with outstanding groups (#TeamScience) to address some key questions in kidney cancer immunobiology: Can we use machine-learning approaches to classify RCC and predict response? Cancer Cell What drives exceptional response with immunotherapies?